<SEC-DOCUMENT>0001753926-23-000557.txt : 20240314
<SEC-HEADER>0001753926-23-000557.hdr.sgml : 20240314
<ACCEPTANCE-DATETIME>20230501161708
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001753926-23-000557
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chromocell Therapeutics Corp
		CENTRAL INDEX KEY:			0001919246
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				863335449
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		685 US HIGHWAY ONE
		CITY:			NORTH BRUNSWICK
		STATE:			NJ
		ZIP:			08902
		BUSINESS PHONE:		9176446313

	MAIL ADDRESS:	
		STREET 1:		685 US HIGHWAY ONE
		CITY:			NORTH BRUNSWICK
		STATE:			NJ
		ZIP:			08902
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><IMG SRC="img001_v2.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chromocell
Therapeutics Corporation<BR>
4400 Route 9 South, Suite 1000<BR>
Freehold, NJ 07728</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
1, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Via
EDGAR</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lauren
Sprague Hamill and Jason Drory</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Securities and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporation Finance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
of Life Sciences</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100
F Street, NE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chromocell
                                         Therapeutics Corporation</B><BR>
                                         <B>Registration Statement on Form S-1 </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
January 11, 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File
No. 333-269188</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Madam and Sir:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
correspondence responds to the letter, dated January 23, 2023, received from the staff of the Securities and Exchange Commission
(the &ldquo;Staff&rdquo;) regarding the abovementioned Registration Statement on Form S-1 filed on January 11, 2023 by Chromocell
Therapeutics Corporation (the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo; or &ldquo;our&rdquo;). For convenience,
the Staff&rsquo;s comments are restated below in bold text, with each comment followed by our response. We are concurrently filing
with this letter Amendment No. 2 to Registration Statement on Form S-1 (&ldquo;Amendment No. 2&rdquo;). Capitalized terms used,
but not defined, in this letter have the meanings ascribed to such terms in Amendment No. 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Registration
Statement on Form S-1 filed January 11, 2023 </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Cover
Page</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="text-align: justify; padding-right: 0.15in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
                                         note that you have applied to list your common stock on the Nasdaq Global Market. Please
                                         revise the cover page of the IPO Prospectus as follows:</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.05in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>State
                                         that no assurance can be given that your listing application will be approved, as you
                                         have on page 89.</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.2in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>State
                                         that your offering is contingent upon final approval of your NASDAQ listing and that
                                         the offering will terminate absent receipt of such approval, as you have on page 4.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
ensure your disclosure is consistent with your underwriting agreement.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Response:
In response to the Staff&rsquo;s comment, we have revised the disclosure on the cover page of Amendment No. 2 accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chromocell
Therapeutics Corporation<BR>
May 1, 2023<BR>
Page 2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>According
                                         to your preliminary fee table and disclosure on pages 7 and 105, it appears that you
                                         will issue warrants to your underwriter, Maxim Group LLC, and warrants to your financial
                                         advisor, A.G.P./Alliance Global Partners, and seek to register these warrants and common
                                         stock underlying these warrants as part of your initial public offering registration
                                         statement. If true, please revise your cover page and offering summary to clarify the
                                         issuance and registration of these warrants and underlying common stock or otherwise
                                         advise.</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Response:
We respectfully advise the Staff that only the common stock underlying the Representative&rsquo;s Warrants and the Advisor Warrants,
but not the Representative&rsquo;s Warrants and the Advisor Warrants, are being registered as part of the initial public offering.
We have revised the cover page and Exhibit 107 accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>The
price of our securities may be volatile and fluctuate substantially . . ., page 36</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
                                         note recent instances of extreme stock price run-ups followed by rapid price declines
                                         and stock price volatility seemingly unrelated to company performance following a number
                                         of recent initial public offerings, particularly among companies with relatively smaller
                                         public floats. As such:</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
                                         revise this risk factor or include a separate risk factor addressing the potential for
                                         rapid and substantial price volatility and any known factors specific to your offering
                                         that may add to this risk.</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.05in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clarify
                                         that any such volatility, including any stock-run up, may be unrelated to your actual
                                         or expected operating performance and financial condition or prospects, which could make
                                         it difficult for prospective investors to assess the rapidly changing value of your stock.</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discuss
                                         the risks to investors when investing in securities where the price may change rapidly.</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Response:
In response to the Staff&rsquo;s comment, we have revised the disclosure on page 33 of Amendment No. 2 accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.55in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations Critical Accounting Policies, page 52 </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.55in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="text-align: justify; padding-right: 0.05in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
                                         reference the disclosure on page 52 and F-21 that the valuation of the intellectual property
                                         related to Chromocell Holding&rsquo;s NaV1.7 program and its clinical-stage CC8464 lead
                                         compound was valued at $44,808,301 by an outside valuation firm based on the cost approach
                                         of valuation. Please tell us the nature and extent of the specialist&rsquo;s involvement
                                         and whether you believe the specialist was acting as an expert as defined under Section11(a)
                                         of the Securities Act of 1933 and Section 436(b) of Regulation C, such that you must
                                         disclose the name of the specialist in the Form S-1 along with a consent from the specialist.
                                         If you conclude the specialist is not considered an expert under the Securities Act,
                                         please revise your disclosures to clarify.</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chromocell
Therapeutics Corporation<BR>
May 1, 2023<BR>
Page 3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Response:
The Company respectfully acknowledges the Staff&rsquo;s comment. We respectfully advise the Staff that prior accounting treatment
of the acquisition treatment and fair value as of and for the period ending September 30, 2022 was preliminary and pursuant to
our final analysis, we determined that historical book value was warranted. Correspondingly, the financial statements as of and
for the period ended December 31, 2022 are presented in a manner that recognizes the historical book value, obviating the fair
value analysis and the need for an outside expert or other party to assist in the valuation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Unaudited
Condensed Consolidated Financial Statements of Chromocell Therapeutics Corporation</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Note
6. Intangible Assets, page F-21 </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="text-align: justify; padding-right: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
                                         revise the disclosure to clearly explain your accounting for the intangible assets acquired
                                         through the contribution agreement in August 2022. Please address the following:</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Disclose
                                         how you valued the intangible assets, including the specific assumptions that were used
                                         in the valuation;</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discuss
                                         the basis for a valuation in excess of $44 million;</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.65in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identify
                                         the accounting literature upon which you relied in determining your accounting for the
                                         acquisition of the intangible assets;</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.05in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tell
                                         us whether the contribution agreement is between entities under common control and how
                                         that impacted your accounting. In that regard, please address how you considered that
                                         the contributed assets should not be recorded at their historical amounts on the Contribution
                                         Date;</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Explain
                                         the basis for the 12 year useful life of the intangible asset.</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Response:
The Company respectfully acknowledges the Staff&rsquo;s comment. We respectfully advise the Staff that, similar to our response
to comment 4 above, the Company&rsquo;s final accounting treatment recognizes the transferred intangible assets at historical
book value, obviating the need for and results of a valuation analysis and determination of fair value and eliminating the amortization
of the fair value over the useful life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you have any questions or require additional information, please contact the Company&rsquo;s counsel, David E. Danovitch at (212)
660-3060 or at ddanovitch@sullivanlaw.com or Aaron M. Schleicher at (212) 660-3034 or at aschleicher@sullivanlaw.com, of Sullivan
&amp; Worcester LLP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 62%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chromocell
    Therapeutics Corporation </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Christian Kopfli</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christian
    Kopfli</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc:</FONT></TD>
    <TD STYLE="width: 97%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristin
    Lochhead and Daniel Gordon, Securities and Exchange Commission</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    E. Danovitch, Esq., Sullivan &amp; Worcester LLP </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
    M. Schleicher, Esq., Sullivan &amp; Worcester LLP</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img001_v2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img001_v2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ *0#Z P$1  (1 0,1 ?_$ *0   (#  ,! 0
M       (!08' @,$ 0D! 0$!  ,! 0             ! @0%!@,'$  ! P,"
M @0'"0X#"0$    ! @,$ !$%!@<A$C%!$PA182(R<A0T<;'!0C-3<W0U@:'1
M4F+"([/#5-05-C>"LA:1DJ+2DR24)A<8$0$!  (!! (!!0$          0(#
M$4$2! 4A,3)184(3,P;_V@ , P$  A$#$0 _ &IH"@\6;F.PL/.FL@%V-'=>
M;"O-*FT%0O:W"XH%CQW>EW!DSHC#D'&!#[S32REMZX"UA)M=WQT7@U(Z*(*
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LT;W ?8D+T!1*\6I?/8]P_!0@TU\H_P"BGX:%1^2^T)'I? *$>?\ Y**__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
